Riccardo must now be aware how much of a backwater the ASX is when it comes to clinical biotechs.
Despite the positive announcements of late RAD in retreat
Had RAD been listed on the NASDAQ then the ASX would has most likely responded like a wagging tail of the US hound
Want evidence of this just take a look at IMC after FDA hold was removed vol & SP up strongly on the NASDAQ listing, the ASX responds with modest gains.
News: RAD Radiopharm Theranostics Says U.S. FDA Granted Orphan Drug Designation To GA68-TRIVEHEXIN, page-18
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
0.001(1.92%) |
Mkt cap ! $57.58M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.8¢ | 2.6¢ | $39.05K | 1.450M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 2712781 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 400000 | 1 |
View Market Depth
| Last trade - 15.59pm 15/10/2024 (20 minute delay) ? |
| RAD (ASX) Chart |